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Live-Virus Challenge
E. JAMES STOTT,"' L. ANDREW BALL,3 KAREN K. YOUNG,' JULIE FURZE,2 AND GAIL W. WERTZ'*
University of North Carolina, Chapel Hill, North Carolina 275141; University of Wisconsin, Madison, Wisconsin 537063;
and Institute for Research on Animal Diseases, Compton RG16 ONN, United Kingdom2
Recombinant vaccinia virus vectors were constructed which expressed the major surface glycoprotein G of
human respiratory syncytial (RS) virus. The biological activity of the G protein expressed from these vectors
was assayed. Inoculation of rabbits with live recombinant virus induced high titers of antibody which
specifically immunoprecipitated RS virus G protein and was capable of neutralizing RS virus infectivity.
Immunization of mice by either the intranasal or the intraperitoneal route with recombinant virus that
expressed only the G protein resulted in complete protection of the lower respiratory tract upon subsequent
challenge with live RS virus.
Human respiratory syncytial (RS) virus causes annual
epidemics of severe lower-respiratory-tract disease in the
pediatric population. Previous attempts to control the dis-
ease by development of vaccines have not been successful
(3, 18). In particular, a vaccine prepared from formaldehyde-
inactivated virus resulted in excess morbidity and mortality
when tested in children (18). At the time this vaccine was
prepared, a complete catalog of RS virus gene products was
not available and little was known about the surface antigens
of the virus. The failure of the vaccine to protect, and
especially the observation that it resulted in exacerbated
disease, emphasized the need to determine all of the anti-
genic components of RS virus and to characterize the
possible roles of each of these proteins in both pathogenesis
of the disease and defense against the disease before at-
tempting to develop an effective vaccine.
The cDNA cloning of the viral mRNAs led to important
advances in understanding the molecular biology of human
RS virus. RS virus was shown to possess 10 genes; the
proteins encoded by each of these genes was identified, and
a transcriptional map of the virus was established (7, 9, 10).
RS virus has two surface glycoproteins (14, 23). One is a
disulfide-linked protein, designated F, which causes fusion
of infected cells (34). F protein has N-linked oligosaccharide
chains, an amino-terminal signal sequence, and a carboxy-
terminal anchor sequence (8, 12). Thus, the overall structure
of F is similar to that of other paramyxovirus fusion proteins
(5). However, the second glycoprotein, G, of human RS
virus is unlike any previously described paramyxovirus
protein and, indeed, any other viral transmembrane protein
described to date (27, 37). Approximately 60% of the molec-
ular weight of the mature 84,000-molecular-weight (84K) G
protein is contributed by carbohydrate, the majority of
which is 0-linked (37). Consistent with this observation,
30% of the amino acids of G protein are serine or threonine,
the attachment sites for 0-linked side chains. Additionally,
the protein lacks an amino-terminal signal sequence and has
no candidate for a carboxy-terminal anchor sequence. In-
stead, G protein possesses a major hydrophobic domain
between residues 38 and 66 which may serve as the mem-
brane-spanning region (37).
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To investigate the role of this unusual glycoprotein in the
pathogenesis of RS virus disease, we constructed recombi-
nant vaccinia virus (VV) vectors containing a complete
cDNA copy of the G gene (1). In previous work, we reported
that the recombinant vectors expressed high levels of G
protein that was indistinguishable from authentic G protein
in electrophoretic mobility and extent of glycosylation (1).
The G protein expressed from the recombinant vectors was
transported to and expressed on the surface of infected cells.
All of the cells infected with recombinant vectors expressed
G protein on the cell surface (1).
In the present work, we tested the biological activity of the
G protein expressed from recombinant vectors. We found
that G protein expressed from recombinant VV induced
antibody in rabbits that neutralized RS virus and that spe-
cifically precipitated authentic G protein. Moreover, mice
inoculated locally or parenterally with recombinant VV
expressing the G gene were protected against subsequent
challenge with live RS virus.
MATERIALS AND METHODS
Cells and viruses. Human RS virus (A2 strain) was propa-
gated in HEp-2 cells as described previously (16). Wild-type
VV (WR strain) and recombinant VV were propagated in
HEp-2 or thymidine kinase-negative (tk-) 143 cells as de-
scribed previously (17).
Plasmid construction, propagation, and DNA sequence de-
termination. The original sources of the plasmids used in this
work have been described previously (1, 7, 37). All plasmids
were propagated in Escherichia coli HB101, extracted by the
boiling method of Holmes and Quigley (15), and purified,
when indicated, by centrifugation to equilibrium on CsCl-
ethidium bromide gradients. Cloning procedures were per-
formed as described by Maniatis et al. (21). When necessary
during plasmid constructions, DNA fragments were recov-
ered by elution from crushed sodium dodecyl sulfate-
polyacrylamide gel slices or by melting of low-melting-point
agarose gel slices and passage of the eluates through NACS
columns (Bethesda Research Laboratories, Inc.,
Gaithersburg, Md.). Completed plasmids were reintroduced
into E. coli cells that had been made competent for the
uptake of DNA by CaCl2 treatment. DNA sequences were
determined by the chemical method (22) with DNA frag-
ments end labeled with reverse transcriptase.
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Isolation of recombinant VV vectors. Plasmids which con-
tained sequences to be recombined into the VV genome
were purified as described above, and calcium phosphate
coprecipitates containing 5 ,ug of plasmid DNA were added
to the medium overlaying 60-mm-diameter plates of
confluent VV-infected (multiplicity of infection, 0.1) HeLa
cells 2 h postinfection. After 10 h of incubation at 37°C, the
medium was replaced, and the infected cells were harvested
into their medium at 48 to 72 h postinfection. The cells were
lysed by freezing and thawing three times, and 1- or 10-,ul
portions of the lysates were used to infect 100-mm plates of
confluent 143 cells under tk--selective conditions. After 48 h
of incubation, individual tk- VV plaques (which remain
compact even in the absence of an agar overlay) were picked
and used to infect 12-mm monolayers of 143 cells in 24-well
tissue culture plates. After 48 h of incubation, the medium
was removed from individual wells and stored at -20°C for
subsequent use as inocula. The infected cells were lysed and
dissolved in saturated sodium iodide, and the DNA was
subjected to the quick-blot procedure of Gillespie et al. (13).
Virus in the medium from wells containing DNA that gave
positive hybridization signals when probed for RS virus
G-specific sequences was taken through two further rounds
of plaque purification and quick-blot hybridization, until
100% of the third plaque-purified virus was positive. The
high initial background of nonrecombinant tk- virus was due
most likely to the mutagenic activity of bromodeoxyuridine
for the tk+ virus. Thrice plaque-purified recombinants were
propagated on HEp-2 cells under nonselective conditions to
yield virus stocks of 109 PFU/ml.
Analysis of protein expression. Proteins synthesized in
infected cells were labeled with [3H]glucosamine and ana-
lyzed by electrophoresis in 12.5% polyacrylamide gels either
directly or following immune precipitation with horse anti-
RSV antiserum as described previously (1).
Production and characterization of antibody in rabbits
immunized with recombinant VV. New Zealand White rab-
bits were used for production of antisera. The upper left hind
limbs were shaved, and wild type (wt) or recombinant VV
was introduced by scarification with a bifurcated needle.
Animals were bled prior to vaccination and at intervals
postinoculation by venipuncture of the central ear vein. The
erythrocytes were allowed to clot overnight at 4°C and then
pelleted for 10 min at 250 x g. At 10 weeks postinoculation,
animals were reinoculated in the same manner. Antibody
titers in these sera were assayed by the enzyme-linked
immunosorbent assay (ELISA). Virus neutralization was
determined by a 50% endpoint plaque reduction assay in
which heat-inactivated (56°C, 30 min) rabbit serum was
incubated for 30 min at room temperature with RS virus
strain A2. Plaque assays were carried out on HEp-2 cells.
In Vivo protection of mice. The ability of VV recombinants
containing the G gene to protect animals was investigated by
using a mouse model of RS virus infection described previ-
ously (32). BALB/c mice (in groups of 10) were vaccinated
intraperitoneally, or intranasally while anaesthetized, with
107 PFU of either vAG301 or wt vaccinia virus. An unvac-
cinated group of 10 mice acted as control. Three weeks after
vaccination, 5 mice in each group were challenged intrana-
sally with 104.2 PFU of RSV. Five days later, mice were
killed and their lungs were assayed for RSV by plaque assay
in HEp-2 cells. At the time of challenge, blood was collected
from the remaining five mice in each group. Antibody titers
in these serum samples were assayed by ELISA.
Antibody titration by ELISA. Microtiter plates (Falcon
Microtest III; Becton Dickinson Labware, Oxnard, Calif.)
were coated with RS virus-infected HEp-2 cell lysate or with
uninfected cell lysate as control. After they were washed, a
single series of threefold dilutions of each serum to be
assayed was added to the plates. The bound RS virus-
specific antibody was then detected by adding horseradish
peroxidase coupled to either swine anti-mouse antiserum
(Serotec Laboratories, Banbury, England) or goat anti-
rabbit antiserum (Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, Md.) followed by 3,3',5,5'-tetramethyl benzi-
dine as substrate. The enzyme reaction was stopped by
addition of 2 M sulfuric acid, and the optical density at 450
nm was measured. Specific optical density at 450 nm was
calculated by subtracting values from reaction mixtures with
control antigen from those with RS virus antigen. The
specific optical density was plotted against serum dilution,
and the endpoint was calculated by regression analysis. The
antibody titer was taken as the reciprocal of the dilution
giving twice the background optical density. All antibody
values were the means of determinations with at least five
mice.
RESULTS
Construction of recombinant VV vector plasmids and vi-
ruses. The steps taken to construct the VV vector plasmids
used in this and other (1) work are illustrated in Fig. 1. DNA
fragments bearing either an early promoter derived from the
VV HindlIl F fragment (the F promoter) or an early-late
promoter derived from the 7.5K protein gene (the 7.5K
promoter) were inserted into the EcoRI site near the middle
of the VV tk gene. The subsequent manipulation shown in
Fig. 1 resulted in plasmids that contained unique BamHI and
SmaI sites just downstream of the sites of transcriptional
initiation for the two promoters. A cDNA copy of the RS
virus G protein gene that lacked only 9 base pairs from the 5'
end of the G mRNA sequence (37) was ligated to octameric
BamHI linkers and inserted into the BamHI sites of the two
vector plasmids. The nucleotide sequences at the junctions
between the VV promoters and the RS virus G gene were
determined by the chemical method (22) and are shown in
Fig. 2.
Plasmids that contained sequences to be recombined into
the VV genome were purified and introduced as calcium
phosphate precipitates into HeLa cells infected with wt VV.
The subsequent selection, screening, plaque purification,
and characterization of the recombinant viruses were per-
formed as described in Materials and Methods.
Expression of RSV G protein from recombinant vectors. In
previous work, we reported that recombinant VV vectors
bearing the RS virus G gene produced high levels of G
protein that were expressed on the cell surface (1). Before
testing the immunogenicity of proteins expressed from these
vectors in animals, we characterized the levels of G-protein
expression as a function both of promoter type and of time
and multiplicity of infection in cell culture.
Expression of G protein from recombinant viruses con-
taining either the F promoter (recombinant vector vAG201)
or the 7.5K promoter (recombinant vector vAG301) was
highest at early times after infection (Fig. 3). Expression
from vAG301 was approximately fourfold higher than that
from vAG201 at early times. Expression of G protein from
vAG301 declined to 50% of its original level by 4.5 h
postinfection, but thereafter that level of expression was
maintained for as long as 8 to 10 h postinfection (data not
shown). In contrast to the expression from vAG301, levels of
G-protein expression from vAG201 declined by 3.5 h post-
J. VIROL.
IMMUNIZATION BY RS VIRUS G PROTEIN 609
H P 1. Hind3 + Xhol BE 2. Isolate tk-bearing E 1. BtH
2. PhspAta frageent
p 2. Phphataes RS G2. Phoihatae 3. Ligate 8I~ 3. LigateP
(e171jI.X/Sa
3.Ligat H ,... E B
-01 1. Hind3 + Sail pAnO2.Isolate larger(fragwnt
SB
H
fiatmrit p92 RSV 6 fragunt
FIG. 1. Construction of recombinant VV vector plasmids. The F promoter fragment (1.2 kilobases) was derived from the HindIll F
fragment of VV DNA by using synthetic adaptors to insert EcoRI and SmaI sites at the unique BamHI site. The resulting EcoRI-ended
fragment or that bearing the 7.5K promoter (20) was transferred to the EcoRI site within the VV tk gene, and the HindIII-XhoI subfragment
carrying the modified tk gene was inserted into pBR322 between the HindIII and Sall sites as shown. The BamHI-ended RSV G gene cDNA
was inserted into the unique BamHI site in the vector plasmids to create VV-RS virus recombinant plasmids. Plasmids pAG201 and pAG202
contained the F promoter followed by the RSV G gene in positive and negative orientations, respectively. Plasmid pAG301 contained the 7.5K
promoter followed by the RS virus G gene in positive orientation. Abbreviations: B, BamHI; E, EcoRI; H, HindIII; Sa, Sall; S, SmaI; X,
XhoI.
infection to less than 25% of that seen at earlier times (<10% binant vectors vAG301, vAG201, or vAG202 or with wt VV.
of maximum level). These observations show that the F Beginning at 3 weeks postinoculation and then at intervals
promoter functions predominantly as an early promoter, thereafter, blood was collected and screened by ELISA for
whereas expression from the 7.5K promoter persists until the presence in serum of antibody to RS virus. Antibody
late in infection, as observed by other workers (6). titers of 10`9 and 103.6 in serum were achieved by inoculation
The level of expression of G protein from the recombinant of vAG301 and vAG201, respectively (Fig. 5). These levels
vectors was dependent on the multiplicity of infection (Fig. of antibody remained essentially constant throughout 18
4). By 3 hours postinfection, expression of G protein in cells weeks of observation and were not significantly increased by
infected with recombinant vAG301 at a multiplicity of infec- a second vaccination at 10 weeks. Serum collected from
tion of 25 was approximately equivalent to that in RSV- rabbits prior to inoculation, from rabbits inoculated with
infected cells at 28 h postinfection. recombinant virus having the G gene in the negative orien-
Antigenicity ofG protein expressed by recombinant vectors. tation relative to the promoter (vAG202), or from rabbits
The ability of recombinant vectors to elicit an antibody inoculated with wt VV had no RS virus-specific antibody
response to RS virus G protein was measured initially with titer.
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FIG. 2. Junction nucleotide sequences of recombinant VV vector plasmids. The nucleotide sequences were determined by the chemical
method with DNA fragments labeled at the BamHI sites by filling with dGTP, [a-32P]dATP, and reverse transcriptase. The major
transcriptional initiation site of the 7.5K promoter (33) is indicated by a vertical arrow; that of the F promoter has not been determined. The
sequence of the 7.5K promoter is identical to that reported by Venkatesan et al. (33) but differs from that reported by Mackett et al. (20) in
having an additional A residue 31 base pairs downstream of the transcriptional start site. The BamHI insertion sites and the sequences
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FIG. 3. Analysis of 0-protein expression from recombinant VV
vectors as a function of time and type of promoter. (A) HEp-2 cells
were infected at a multiplicity of infection of with human RS virus
(lane 2), recombinant vAG3O1 (lanes 3, 5, 7, and 9), or recombinant
vAG2O1 (lanes 4, 6, 8, and 10), or were uninfected (lane 1). The cells
infected with recombinants vAG3O1 or vAG2O1 were exposed to
[3H]glusosamine (100 p.Ci/ml) for the following intervals: 2.5 to 3.5
h (lanes 3 and 4), 3.5 to 4.5 h (lanes and 6), 4.5 to 5.5 h (lanes 7 and
8), 5.5 to 6.5 h (lanes 9 and 10), or 27 to 28 h postinfection with RS
virus (lane 2) or uninfected control (lane 1). The labeled proteins
were analyzed by electrophoresis on 12.5% polyacrylamide gels
following immunoprecipitation with anti-RS virus antiserum. A
fluorogram of the dried gel is shown. (B) Relative intensity of label
present in the protein band was compared by densitometric
scanning. Open box, vAG3O1; hatched box, vAG2O1.
nants vAG3O1 and vAG2O1 were used to test the specificity
of the immune response. Sera collected at 3 weeks postin-
oculation from rabbits immunized with recombinant vAG3O1
expressing protein specifically immunoprecipitated pro-
tein from lysates of RS virus-infected cells (Fig. 6). Similar
results were obtained with vAG2O1 (data not shown). Sera
collected from rabbits prior to immunization and from rab-
bits immunized with wt VV or recombinant vAG2O2 did not
precipitate any proteins from RSV-infected cells.
These data demonstrate that antibodies specific for the RS
virus G protein were produced in rabbits in response to
immunization with recombinants expressing the protein.
This serum was tested for its ability to neutralize the
infectivity of RS virus. The 0-protein-specific antibody
collected at 12 weeks from rabbits immunized with recom-
binant vAG3Ol neutralized RS virus in the absence of
complement with a 50% plaque reduction endpoint titer of 64
(Table 1). Sera collected from animals prior to immunization
4'~~~
FIG. 4. Effect of multiplicity of infection on G-protein expres-
sion in HEp-2 cells infected with recombinant VV vector vAG3O1.
HEp-2 cells were infected with human RS virus at a multiplicity of
infection of 5 or recombinant vAG301 at a multiplicity of infection of
2.5, 5, 10, or 24 (lanes 2 through 6 respectively) or with wt VV at a
multiplicity of infection of 8 or 24 (lanes 7 and 8, respectively), or
uninfected as control (lane 1). Cells were labeled from 3 to S h
postinfection with 100 jiCi of [3H]glucosamine per ml. Labeled
proteins were analyzed on a 12.5% polyacrylamide gel without
immunoprecipitation. A fluorogram of the dried gel is shown.
or from animals inoculated with wt VV did not neutralize
virus at a dilution of 1:2.
Recombinant VY is not neutralized by antibody to RS virus.
The RS virus G protein is one of two major virion surface
glycoproteins; it is also expressed on the surface of cells
infected with RS virus or on the surface of cells infected with
recombinant VV virions expressing the G gene. We tested
whether the G protein expressed in recombinant VV-
infected cells might be incorporated into the membrane of
the recombinant VV virions in such a way that antibody to
RS virus G protein could neutralize the recombinant virus.
Horse anti-RSV antibody (Flow Laboratories, Inc., Mc-
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FIG. 5. Antibody production in rabbits inoculated with recombi-
nants vAG3O1 or vAG2O1. Rabbits inoculated intradermally with
recombinant VV vectors were bled at intervals following vaccina-
tion. Serum antibody titers against RS virus were measured by
ELISA. Animals were given a second inoculation at 10 weeks after
the initial injection.
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endpoint titer of 1:40,000 failed to have any neutralizing
activity against either recombinant or wt VV (Table 1).
Vaccination of animals. In view of the higher level of
protein expression and the greater immunogenicity in rabbits
of vAG301, this recombinant was chosen to test for protec-
tion against live intranasal challenge in vivo. Several small-
animal-model systems for RS virus infection have been
described, and two of these, the cotton rat and certain inbred
mice, have been shown to be particularly useful (24, 26, 32).
We chose to use a previously described inbred mouse model
(32) because well-characterized reagents are available which
will eventually allow detailed analysis of specific cellular and
humoral immune responses to RS virus and its proteins.
Groups of 10 mice were inoculated either intranasally or
intraperitoneally with 107 PFU of recombinant vAG301 or wt
VV. An unvaccinated group of mice served as a control.
Mice were challenged intranasally with 104.2 PFU of RS
virus at 3 weeks after vaccination. The results of these
experiments are shown in Table 2. The mice inoculated
intranasally with wt VV developed ruffled coats and became
lethargic 3 days after vaccination. Two days later, they were
killed in extremis. All other mice remained healthy; no
lesions were observed in mice inoculated intranasally or
intraperitoneally with recombinant VV. By 3 weeks after
vaccination, all mice given recombinant vAG301 either
intranasally or intraperitoneally had developed high levels of
antibody to RS virus in their serum. Their ELISA titers
ranged from 103.2 to 104-3 (means, 3.9 [intraperitoneal] and
3.6 [intranasal]). Antibody was not detectable in unvac-
cinated mice or in those given wt VV.
After intranasal challenge with RS virus, high titers of RS
virus were found in the lungs of all unvaccinated mice and in
those given wt VV intraperitoneally. RS virus was not
1 2 3 4 5 6
Fo-
F2
FIG. 6. Analysis of sera from rabbits immunized with recombi-
nant virus by immunoprecipitation. Sera collected from rabbits prior
to immunization or 3 weeks after immunization with recombinant
vAG301 or wt VV was used to immunoprecipitate proteins labeled
with [3H]glucosamine from RS virus-infected cell lysates. Sera used
were as follows: lane 1, horse anti-RS virus (Flow Laboratories);
lane 2, rabbit 378 (anti-vAG301, undiluted); lane 3, rabbit 378
(anti-vAG301 diluted 1:10); lane 4, rabbit 377 (anti-wt VV, undi-
luted); lane 5, rabbit 377 (anti-wt VV diluted 1:10): lane 6, sera from
rabbit 378 (vAG301) prior to immunization.
TABLE 1. Neutralization of RS virus or recombinant VV
Virus Antibody Neutralizing titera
RS virus prelmm rabbit 378 sera <2
RS virus Rabbit 378 anti-vAG301 64
wt VV Horse anti-RS virus <2
vAG301 Horse anti-RS virus <2
RS virus Horse anti-RS virus 40,000
a Reciprocal 50% plaque reduction end point.
detected in the lungs of mice vaccinated with recombinant
vAG301 by either the intranasal or intraperitoneal route.
These data demonstrate that vaccination with recombinant
vectors expressing RS virus G protein confers protection
against RS virus challenge in vivo.
DISCUSSION
The strategy we have taken to determine which antigens of
human RS virus might be important in viral infection and
immunity is that of expressing the proteins individually or in
concert by using eucaryotic expression vectors. By this
means, the ability of each protein to elicit a protective
immune response can be tested. We chose to use VV vectors
because of their versatility, wide host range, and cytoplas-
mic location of replication.
In earlier work, we showed that recombinant VV that
contain cDNAs corresponding to the RS virus G gene
synthesized the G protein in a form that appeared to be fully
glycosylated and which was expressed at the surface of
infected cells (1). The two VV promoters that we tested
differed in the levels of G protein that they directed. Despite
making much more G-specific early mRNA (1), the recom-
binant using the F promoter (vAG201) made lower initial
levels of G protein than the recombinant using the 7.5K
promoter (vAG301), and the G-protein synthesis stopped
earlier (Fig. 3). The nucleotide sequence of the F promoter
(Fig. 2) offers a probable explanation for the lower transla-
tional activity of its recombinant transcripts. Two ATG
codons occur just upstream of the BamHI insertion site and
lie in sequence contexts that are characteristic of strong
translation initiation sites (19). Their reading frame is the
same but differs from that of the inserted G gene, so that
their presence in the recombinant mRNA would be expected
substantially to inhibit translation from the authentic G
protein start codon (19). In addition, the more prolonged
expression directed by the 7.5K promoter can be attributed
to the observation that this promoter functions at both early
TABLE 2. Vaccination of mice with recombinant vAG301
and wt VV
Vaccine Routea RS virus antibody Virus titer in
virus titer in serumb lungsc
vAG301 i.n. 3.6 ± 0.23 <1.7
wt VV i.n. _d
vAG301 i.p. 3.91 ± 0.19 <1.7
wt VV i.p. <1.5 4.49 ± 0.13
None <1.5 4.31 ± 0.21
a i.n., intranasal; i.p., intraperitoneal.
bELISA titers at 21 days after vaccination expressed as logio mean +
standard error.
c Titers at 5 days after challenge expressed as mean loglo pfu per gram (wet
weight) of lung ± s.e.
d -, These mice were killed in extremis 5 days after vaccination.
VOL. 60, 1986
612 STOTT ET AL.
and late times during infection (6), whereas the F promoter
appears to function at early times only.
Recombinant vAG301 which uses the 7.5K promoter was
chosen to assay the biological activity of expressed G
protein in animals. When inoculated into rabbits, vAG301
stimulated the production of ELISA titers of 10`9 of anti-
body specific for authentic RS virus G protein by 3 weeks
postinoculation. This antibody neutralized RS virus infectiv-
ity, although with a modest titer.
Intranasal or intraperitoneal inoculation of recombinant
vAG301 into mice completely protected their lungs against
RS virus challenge 3 weeks later. The mechanism by which
protection was mediated is not clear. It has been shown that
passive transfer of monoclonal antibody to G glycoprotein is
sufficient to protect against challenge with RS virus in mice
and cotton rats (30, 35). Certainly, the data presented here
show correlation between the presence of high titers of
antibody to G protein and protection. It is probable, how-
ever, that neutralization of infecting virus is not the sole
mechanism by which protection can be mediated in mice.
Antibody to G glycoprotein also will bind to virus-infected
cells that then may be killed either by complement lysis or
antibody-dependent cell cytotoxicity (28). Additionally, the
presence of RS virus-specific cytotoxic T cells has been
demonstrated in mice infected with RS virus (2), and there is
evidence to suggest that cytotoxic T cells are necessary to
eliminate RS virus infections in athymic nude mice (M. J.
Cannon, E. J. Stott, and B. Askonas, manuscript in prepa-
ration). However, preliminary evidence obtained from use of
VV recombinant vAG301 indicates that G protein is not a
major target for cytotoxic T cells in either the mouse or the
human system (C. Bangham, P. Openshaw, A. M. Q. King,
L. A. Ball, G. Wertz, and B. Askonas, J. Immunol., in
press).
Another study of a recombinant VV expressing RS virus G
protein was reported while this manuscript was in prepara-
tion (11). In that study, cotton rats were immunized by an
intradermal route and 88% protection against lower-
respiratory-tract infection was achieved (11). While it is
difficult to directly compare this work with our study be-
cause of the different animal models, different recombinants,
and different routes of inoculation used, it should be noted
that immunization by the intranasal and intraperitoneal
routes used 30-fold less recombinant virus and gave com-
plete lower-respiratory-tract protection. This protection cor-
related with a mean antibody titer in serum that was more
than 170-fold higher than background levels. In the study in
which intradermal inoculation was used, the antibody titer in
serum was increased less than 40-fold (11). Thus, the reason
for the complete protection of mice which was induced by
vAG301 might be that this recombinant is a more efficient
expression vector than that used by Elango et al. (11).
Alternatively, virus given intranasally or intraperitoneally
may stimulate a greater protective response than that given
intradermally. Small et al. (29) showed that intranasal inoc-
ulation of a recombinant VV bearing the influenza HA gene
conferred protection on both the upper and lower respiratory
tracts of animals, whereas intradermal inoculation protected
only the lower respiratory tract. Studies to compare directly
the efficacy of protection as a function of the route of
inoculation in both mice and cotton rats are under way.
It is possible that surface proteins encoded by foreign
genes in the recombinants are inserted into the VV coat and
alter the tissue tropism of the virus. Since the G glycoprotein
is thought to be the attachment protein of RS virus (36), its
incorporation into VV might be expected to enhance tropism
for the respiratory tract. However, since vAG301 caused no
overt clinical disease when inoculated intranasally and was
not neutralized by antiserum to RS virus, it seems unlikely
that glycoprotein G was incorporated into vAG301 virus coat
in a manner which grossly altered its biological behavior.
Our observation that vAG301 given intranasally was less
virulent than wt VV corroborates a previous report that VV
recombinants lacking the tk gene are significantly attenuated
when inoculated intracerebrally or intraperitoneally into
mice (4).
The protection induced in mice 3 weeks after a single dose
of vAG301 expressing only the G protein of RS virus is
impressive and shows the efficacy of this recombinant in
eliciting a protective reponse. This work indicates that
individual components of RS virus expressed in an appro-
priate manner may be used to develop strategies for a
successful vaccine. However, before that can be done,
important questions remain to be answered concerning RS
virus pathogenesis and disease. One prominent problem
comes from the observation that an inactivated virus vaccine
tested in the 1960s caused increased severity of disease (18).
The cause of this vaccine-induced disease is still unknown
(25) and must be established. VV recombinants expressing
individual proteins are powerful tools with which the im-
mune response may be analyzed, and antigens that elicit
potentially harmful responses may be differentiated from
those that protect.
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